← Back
Data updated: Mar 10, 2026
Eli Lilly
LLY MetabolicOncologyImmunology
Indianapolis-based pharma with leading positions in diabetes (Mounjaro, Trulicity) and Alzheimer's (Donanemab). Fast-growing obesity franchise with Zepbound.
$41.3B
Revenue (2024)
$750.0B
Market Cap
-
Trials
150
Approved (2yr)
Key Drugs
Recent Activity
ZEPBOUND 2026-02-25
Labeling
HEPARIN SODIUM 2026-02-20
Labeling
HEPARIN SODIUM 2026-02-20
Labeling
MOUNJARO 2026-01-20
Labeling
ZEPBOUND 2026-01-20
Labeling
MOUNJARO 2026-01-07
Manufacturing (CMC)
ZEPBOUND 2026-01-07
Manufacturing (CMC)
POTASSIUM CHLORIDE 2025-12-22
MOUNJARO 2025-12-19
Efficacy
HUMATROPE 2025-11-25
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Metabolic 44%
14 drugs Phase 3: 94 Phase 2: 30 Phase 1: 104
Oncology 19%
6 drugs Phase 3: 22 Phase 2: 29 Phase 1: 92
Immunology 17%
2 drugs Phase 3: 42 Phase 2: 25 Phase 1: 19
Neurology 11%
2 drugs Phase 3: 24 Phase 2: 12 Phase 1: 18
Dermatology 9%
3 drugs Phase 3: 24 Phase 2: 5 Phase 1: 6
Pipeline Strength Pro
Loading...
Active (47)
INLURIYO EBGLYSS KISUNLA ZEPBOUND ZEPBOUND KWIKPEN ZEPBOUND (AUTOINJECTOR) OMVOH MOUNJARO MOUNJARO KWIKPEN MOUNJARO (AUTOINJECTOR) REZVOGLAR LYUMJEV RETEVMO REYVOW EMGALITY OLUMIANT VERZENIO LARTRUVO TALTZ BASAGLAR PORTRAZZA TRULICITY CYRAMZA ADCIRCA ALIMTA CIALIS FORTEO HUMALOG MIX 50/50 KWIKPEN HUMALOG MIX 50/50 HUMALOG MIX 75/25 HUMALOG MIX 75/25 KWIKPEN EVISTA HUMALOG KWIKPEN HUMALOG TEMPO PEN HUMALOG HUMULIN 70/30 PEN HUMULIN 70/30 PROZAC HUMULIN R PEN HUMULIN R HUMULIN R KWIKPEN HUMULIN N ERYTHROMYCIN AMPICILLIN SODIUM NEOMYCIN SULFATE GLUCAGON PROPYLTHIOURACIL
Discontinued (81)
HEPARIN SODIUM POTASSIUM CHLORIDE HUMATROPE PROGESTERONE QUINIDINE SULFATE FOLIC ACID METHYLTESTOSTERONE HUMALOG PEN ISONIAZID SYMBYAX SULFADIAZINE SARAFEM CYMBALTA HUMALOG MIX 50/50 PEN HUMALOG MIX 75/25 PEN STREPTOMYCIN SULFATE QUINIDINE GLUCONATE STRATTERA GEMZAR PENICILLIN G POTASSIUM SECONAL SODIUM AXIRON PROZAC WEEKLY TESTOSTERONE PROPIONATE BACITRACIN MANDOL KEFZOL VELBAN NEBCIN ONCOVIN TAZIDIME IN PLASTIC CONTAINER CINOBAC DYNABAC TAZIDIME PROTAMINE SULFATE CECLOR KEFUROX DOBUTREX TUBOCURARINE CHLORIDE METUBINE IODIDE KEFTAB CECLOR CD AVENTYL HYDROCHLORIDE CALCIUM GLUCEPTATE DYMELOR ILOSONE DICUMAROL HALDRONE V-CILLIN K KEFUROX IN PLASTIC CONTAINER
+31 more
Company Info
- First Approval
- 1939-03-09
- Latest
- 2026-02-25
- Applications
- 142
FDA Sponsor Names
LILLYELI LILLY AND COELI LILLY COLILLY RES LABS